{"id":10841,"date":"2023-12-08T00:12:00","date_gmt":"2023-12-07T16:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10841"},"modified":"2024-11-02T00:15:04","modified_gmt":"2024-11-01T16:15:04","slug":"medtronic-exits-738-million-deal-to-acquire-eoflow-amid-regulatory-and-legal-challenges","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10841","title":{"rendered":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges"},"content":{"rendered":"\n

U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea’s EOFlow (KOSDAQ: 294090<\/a>), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share purchase and subscription agreements, as well as a public tender offer contingent on minimum tender conditions and regulatory approvals. Medtronic cited multiple breaches of these terms as the reason for terminating the deal, asserting that no termination fee is owed.<\/p>\n\n\n\n

EOFlow is known for its EOPatch insulin delivery system, which integrates a glucose monitoring sensor, insulin pump, and automated insulin delivery algorithm. This product has already received approval in South Korea and Europe and is currently under U.S. review, having earned breakthrough device designation from the FDA.<\/p>\n\n\n\n

While the specifics of the “multiple breaches” have not been disclosed, speculation suggests that ongoing legal challenges to the EOPatch’s patent from rival insulin pump manufacturer Insulet may have influenced Medtronic’s decision. These legal disputes have resulted in injunctions against EOFlow’s product in both the U.S. and Germany this year. Medtronic’s SEC filing indicates that the company will continue to develop its own insulin dosing product pipeline, which includes plans for a differentiated patch pump.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,61],"tags":[1838,1839],"class_list":["post-10841","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-legal-ip","tag-eoflow","tag-kosdaq-294090"],"yoast_head":"\nMedtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea's EOFlow (KOSDAQ: 294090), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share purchase and subscription agreements, as well as a public tender offer contingent on minimum tender conditions and regulatory approvals. Medtronic cited multiple breaches of these terms as the reason for terminating the deal, asserting that no termination fee is owed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10841\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-07T16:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-01T16:15:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges\",\"datePublished\":\"2023-12-07T16:12:00+00:00\",\"dateModified\":\"2024-11-01T16:15:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"EOFlow\",\"KOSDAQ: 294090\"],\"articleSection\":[\"Company\",\"Deals\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10841#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10841\",\"name\":\"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-07T16:12:00+00:00\",\"dateModified\":\"2024-11-01T16:15:04+00:00\",\"description\":\"U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea's EOFlow (KOSDAQ: 294090), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share purchase and subscription agreements, as well as a public tender offer contingent on minimum tender conditions and regulatory approvals. Medtronic cited multiple breaches of these terms as the reason for terminating the deal, asserting that no termination fee is owed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10841\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges - Insight, China's Pharmaceutical Industry","description":"U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea's EOFlow (KOSDAQ: 294090), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share purchase and subscription agreements, as well as a public tender offer contingent on minimum tender conditions and regulatory approvals. Medtronic cited multiple breaches of these terms as the reason for terminating the deal, asserting that no termination fee is owed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10841","og_locale":"en_US","og_type":"article","og_title":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10841","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-07T16:12:00+00:00","article_modified_time":"2024-11-01T16:15:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10841#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10841"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges","datePublished":"2023-12-07T16:12:00+00:00","dateModified":"2024-11-01T16:15:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10841"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["EOFlow","KOSDAQ: 294090"],"articleSection":["Company","Deals","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10841#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10841","url":"https:\/\/flcube.com\/?p=10841","name":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-07T16:12:00+00:00","dateModified":"2024-11-01T16:15:04+00:00","description":"U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire South Korea's EOFlow (KOSDAQ: 294090), a developer of wearable insulin pumps. According to a recent SEC filing, the original agreement, signed in May 2023 and valued at up to USD 738 million, included separate share purchase and subscription agreements, as well as a public tender offer contingent on minimum tender conditions and regulatory approvals. Medtronic cited multiple breaches of these terms as the reason for terminating the deal, asserting that no termination fee is owed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10841"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10841"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10841\/revisions"}],"predecessor-version":[{"id":10842,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10841\/revisions\/10842"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}